Lercanidipine

Lercanidipine

Clinical data
ATC code	C08CA13 (WHO)
Identifiers
IUPAC name methyl[2-(3,3-diphenylpropyl-methyl-amino)- 1,1-dimethyl-ethyl] 2,6-dimethyl- 4-(3-nitrophenyl)- 1,4-dihydropyridine-3, 5-dicarboxylate
CAS Number	100427-26-7
PubChem CID	65866
DrugBank	APRD00193
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C36H41N3O6
Molar mass	611.727 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Lercanidipine is a calcium channel blocker of the dihydropyridine class.

It is sold under various commercial names including Zanidip.

Further reading

• Lin T, Voon W, Yen H, Huang C, Su H, Lai W, Sheu S (2006). "Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters". Kaohsiung J Med Sci. 22 (4): 177–83. PMID 16679299.CS1 maint: Multiple names: authors list (link)
• Martinez M, Lopes L, Coelho E, Nobre F, Rocha J, Gerlach R, Tanus-Santos J (2006). "Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension". J Cardiovasc Pharmacol. 47 (1): 117–22. PMID 16424795.CS1 maint: Multiple names: authors list (link)
• Agrawal R, Marx A, Haller H (2006). "Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension". J Hypertens. 24 (1): 185–92. PMID 16331117.CS1 maint: Multiple names: authors list (link)

External links

• Template:DiseasesDB

Template:WikiDoc Sources